Croda acquires market-leading vaccine adjuvant specialist

17 Dec 2018

Croda will not only gain ownership to Biosector’s rich development pipeline but will become the only adjuvant supplier in the world with an aseptic and GMP-certified manufacturing site for vaccine adjuvants.

Croda International has strengthened its pharmaceutical offering by signing a definitive agreement with Brenntag Nordic to acquire Brenntag Biosector (Biosector), for a total consideration of €72 million in cash. This transaction is expected to close by the end of 2018.

Croda acquires market-leading vaccine adjuvant specialist

Founded in 1939, Biosector has unprecedented industry experience as a vaccine adjuvant specialist, with their product portfolio comprising innovative aluminium- and saponin-based adjuvants. The Biosector team, based in Frederikssund, Denmark will be welcomed to the Croda group and continue to be led by Managing Director Peter Tygesen.

Vaccine adjuvants are a complimentary extension of Croda’s existing pharmaceutical excipients portfolio within their Health Care business. The acquisition of Biosector will give Croda access to an industry renowned product portfolio of adjuvants, including the well-known brands Alhydrogel and Adju-Phos, as well as their technically advanced saponin-based adjuvant systems. Through this acquisition, Croda will not only gain ownership to Biosector’s rich development pipeline for second and third generation adjuvant platforms but will also become the only adjuvant supplier in the world with an aseptic and GMP-certified manufacturing site for vaccine adjuvants.

Croda will leverage its own dedicated global sales network to accelerate Biosector’s growth. Furthermore, the acquisition will enable Croda to better support their existing customers through increased breadth of offering and additional technical expertise in vaccine adjuvants.

Nick Challoner, President of Life Sciences at Croda commented: “Biosector is a rare asset in a high-value, fast-growing sector of the global pharmaceutical market. With an experienced team, Biosector brings world-class innovation and industry-leading manufacturing facilities. The opportunity to quickly build upon Biosector’s impressive track record via our global sales network is enormously exciting and we look forward to welcoming the team to Croda.”

Peter Tygesen, Managing Director Biosector, said: “Croda share our passion for exciting innovation. Under the Croda umbrella we look forward to continuing to grow and further establish our research and development into high-quality industry-leading adjuvant platforms.”

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Operations commence at Wasdell Group’s EU headquarters

Operations commence at Wasdell Group’s EU headquarters

8 Jul 2019

The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

Read more 
Porvair Sciences launches first Drosophila ChIP kits

Porvair Sciences launches first Drosophila ChIP kits

4 Jul 2019

Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.

Read more 
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

3 Jul 2019

Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

2 Jul 2019

The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.

Read more 
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

1 Jul 2019

Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

Read more